{
    "root": "7e27e3f6-e160-49d7-9f34-9c7e2cfa299b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clarithromycin",
    "value": "20250310",
    "ingredients": [
        {
            "name": "CLARITHROMYCIN",
            "code": "H1250JIK0A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X"
        },
        {
            "name": "SORBIC ACID",
            "code": "X045WJ989B"
        }
    ],
    "indications": "clarithromycin tablets macrolide antimicrobial indicated mild moderate infections caused designated , susceptible bacteria following : • acute bacterial exacerbation chronic bronchitis adults ( 1.1 ) • acute maxillary sinusitis ( 1.2 ) • community-acquired pneumonia ( 1.3 ) • pharyngitis/tonsillitis ( 1.4 ) • uncomplicated skin skin structure infections ( 1.5 ) • acute otitis media pediatric patients ( 1.6 ) • treatment prophylaxis disseminated mycobacterial infections ( 1.7 ) • helicobacter pylori infection duodenal ulcer disease adults ( 1.8 ) limitations reduce development drug-resistant bacteria maintain effectiveness clarithromycin tablets antibacterial drugs , clarithromycin tablets used treat prevent infections proven strongly suspected caused bacteria . ( 1.9 )",
    "contraindications": "• adults : clarithromycin tablets 250 mg 500 mg every 12 hours 7 14 days ( 2.2 ) • h. pylori eradication ( combination lansoprazole/amoxicillin , omeprazole/amoxicillin , omeprazole ) : clarithromycin tablets 500 mg every 8 12 hours 10 14 days . full prescribing information ( fpi ) additional information . ( 2.3 ) • pediatric patients : clarithromycin tablets 15 mg/kg/day divided every 12 hours 10 days ( 2.4 ) • mycobacterial infections : clarithromycin tablets 500 mg every 12 hours ; clarithromycin tablets 7.5 mg/kg 500 mg every 12 hours pediatric patients ( 2.5 ) • reduce dose moderate renal impairment concomitant atazanavir ritonavir-containing regimens severe renal impairment ( 2.6 )",
    "warningsAndPrecautions": "clarithromycin tablets usp , 500 mg light yellow colored , oval shaped , biconvex film-coated tablets , ‘ ’ debossed one side ‘ 63 ’ side . cartons 30 film-coated tablets ( 10 film-coated tablets blister pack x 3 ) , ndc 0904-6872-04 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "• hypersensitivity clarithromycin macrolide ( 4.1 ) • cisapride pimozide ( 4.2 ) • history cholestatic jaundice/hepatic dysfunction clarithromycin ( 4.3 ) • colchicine renal hepatic impairment ( 4.4 ) • lomitapide , lovastatin , simvastatin ( 4.5 ) • ergot alkaloids ( ergotamine dihydroergotamine ) ( 4.6 ) • lurasidone ( 4.7 )",
    "indications_original": "Clarithromycin tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: • Acute Bacterial Exacerbation of Chronic Bronchitis in Adults ( 1.1 ) • Acute Maxillary Sinusitis ( 1.2 ) • Community-Acquired Pneumonia ( 1.3 ) • Pharyngitis/Tonsillitis ( 1.4 ) • Uncomplicated Skin and Skin Structure Infections ( 1.5 ) • Acute Otitis Media in Pediatric Patients ( 1.6 ) • Treatment and Prophylaxis of Disseminated Mycobacterial Infections ( 1.7 ) • Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults ( 1.8 ) Limitations of Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.9 )",
    "contraindications_original": "• Adults: Clarithromycin tablets 250 mg or 500 mg every 12 hours for 7 to 14 days ( 2.2 ) • H. pylori eradication (in combination with lansoprazole/amoxicillin, omeprazole/amoxicillin, or omeprazole): Clarithromycin tablets 500 mg every 8 or 12 hours for 10 to 14 days. See full prescribing information (FPI) for additional information. ( 2.3 ) • Pediatric Patients: Clarithromycin tablets 15 mg/kg/day divided every 12 hours for 10 days ( 2.4 ) • Mycobacterial Infections: Clarithromycin tablets 500 mg every 12 hours; clarithromycin tablets 7.5 mg/kg up to 500 mg every 12 hours in pediatric patients ( 2.5 ) • Reduce dose in moderate renal impairment with concomitant atazanavir or ritonavir-containing regimens and in severe renal impairment ( 2.6 )",
    "warningsAndPrecautions_original": "Clarithromycin Tablets USP, 500 mg are light yellow colored, oval shaped, biconvex film-coated tablets, with ‘D’ debossed on one side and ‘63’ on the other side.\n                  Cartons of 30 film-coated tablets (10 film-coated tablets each blister pack x 3), NDC 0904-6872-04\n                  \n                     Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "• Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) • Cisapride and pimozide ( 4.2 ) • History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) • Colchicine in renal or hepatic impairment ( 4.4 ) • Lomitapide, lovastatin, and simvastatin ( 4.5 ) • Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) • Lurasidone ( 4.7 )"
}